Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

BASKING RIDGE, N.J., April 3, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.  REG1 is a two-component system consisting of pegnivacogin, a highly selective Factor IXa (FIXa) inhibitor and anivamersen, its complementary specific active control agent.

The presentation, "A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-ranging Study Assessing the Safety, Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Weight Heparin in Subjects with Acute Coronary Syndromes: Primary Results of the RADAR Randomized Clinical Trial," was made by Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University during an i2 Special Session titled "Interventional Featured Clinical Studies I."  

The international Phase 2b RADAR clinical trial was conducted in subjects admitted for ACS-unstable angina and myocardial infarction without ST-segment elevation (UA/NSTEMI) intended for cardiac catheterization within 24 hours.  The objectives of RADAR were to verify that 1 mg/kg of pegnivacogin resulted in near complete FIXa inhibition, to determine the dose of anivamersen which, when followed by immediate arterial sheath removal, results in a bleeding rate lower than heparin and to assess the efficacy of REG1 (based on ischemic event rates) as an anticoagulant system in an invasively managed ACS population.  The primary endpoint of the study was ACUITY bleeding (major and minor) at 30 days.  A secondary endpoint was
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... SAN JOSE, Calif. , Sept. 17, 2014 ... as a laureate of The Tech Awards 2014, one ... benefit humanity and spark global change. The Tech Awards, a ... by Applied Materials, Inc., selected Gradian as one of two ... - http://photos.prnewswire.com/prnh/20140917/146680 Gradian equips hospitals ...
(Date:9/17/2014)... -- , Glenmark,s first in ... in a Phase 2a proof of concept study in ... Glenmark Pharmaceuticals today announced that its first in ... 17536 has shown positive data in a Phase 2a ... conducted on 138 patients in Europe ...
(Date:9/17/2014)... , Sept. 17, 2014  Millions of people suffer ... disc disease. Recently the FDA approved the ... disc, an innovative implant device developed by Spinal Kinetics, which ... in neck and or arm pain. Hospital for Special Surgery ... the only hospital in New York City ...
Breaking Medicine Technology:Gradian Health Systems Named A 2014 Laureate of The Tech Awards 2Gradian Health Systems Named A 2014 Laureate of The Tech Awards 3Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2
... 10, 2011 Cephalon, Inc. (Nasdaq: CEPH ) ... percent increase compared to net sales of $2.152 billion for ... $5.66.  Excluding amortization expense and certain other items, adjusted net ... percent increase over the previous year.  This exceeded the company,s ...
... Medicare beneficiaries are reporting problems receiving medically required ... 2011 implementation of Medicare,s "competitive" bidding program in Cleveland ... than 640,000 seniors and people living with disabilities in ... The bidding program began in nine areas on ...
Cached Medicine Technology:Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 2Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 3Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 4Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 5Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 6Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 8Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 9Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 10Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 11Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 12Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 13Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 14Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 15Seniors in Ohio Report Problems With Access to Home Medical Equipment and Services Under Controversial Medicare Bidding System 2Seniors in Ohio Report Problems With Access to Home Medical Equipment and Services Under Controversial Medicare Bidding System 3
(Date:9/17/2014)... 2014 (HealthDay News) -- Social networking sites can help ... For people who are obese, sites like Twitter and ... support from doctors as well as peers, researchers found. ... methods is that it offers the potential to be ... when compared to traditional approaches," the study,s lead author, ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... Dallas, TX (PRWEB) September 17, 2014 ... they were recently granted several awards for their top-notch ... regarding patient experience, orthopedic care and GYN surgery. , ... Patient Safety Excellence Award™. They have received this award ... ranked among the top 5 percent in the nation ...
(Date:9/17/2014)... N.J. (PRWEB) September 17, 2014 ... advanced delivery technologies and development solutions for drugs, ... launch of OptiPact™, an integrated service and technology ... compaction, and provided from the company’s 450,000 sq. ... describes Catalent’s ability to integrate optimal formulation, development, ...
(Date:9/17/2014)... Dennis Thompson ... News) -- Exposure in the womb to household chemicals ... of developing asthma, Columbia University researchers reported in a ... increased risk of developing asthma between age 5 and ... high levels of two phthalates (pronounced thal-ates), the researchers ...
Breaking Medicine News(10 mins):Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:North Central Surgical Center Receives Several Accolades 2Health News:New OptiPact™ Technology Introduced by Catalent 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4
... Consumption of supplemental zinc is associated with an increased ... of data from the Health Professionals Follow-up Study. ,The ... soft tissues. However, studies of the effect of zinc ... 46,000 men followed in the health professionals study, there ...
... leprosy, are the world’s most neglected diseases along ... African trypanosomiasis)and Chagas disease, that afflict the deeply ... of the global disease burden however ironically, a ... to these diseases.// , ,In a laudable initiative, ...
... than people who speak English, scientists said on Monday, ... the brain processes language. ,Unlike English speakers, who use ... scientists at the Wellcome Trust research charity in Britain ... to interpret variations in sounds in Mandarin.// ,"We ...
... problem for doctors, but what do they do when the ... to answer in a new study published in this month’s ... years worth of hospital records in Galveston, Texas, identified several ... follow when man bites man. ,The study uncovered 40 human ...
... one to suspect health problems, including heart disease. ... are at higher risk for heart attacks. ,A sore ... notes the Academy of General Dentistry. There's also a ... patients with heart conditions by diagnosing dental problems// that ...
... turn to complementary and alternative medicine, researchers have ... associated with such use. ,In this study, ... enrolled in the HIV Cost and Services Utilization ... conventional HIV care, researchers determined demographic and clinical ...
Cached Medicine News:Health News:ICMR along with other International Research organisation with drug development for Neglected Diseases, 2Health News:,Alternative Therapy in HIV Patients 2
... water perfused manometric catheters for ... diagnostic tests. All Medtronic Water ... clear, medical grade PVC tubing. ... esophagus you will find a ...
Each solid state catheter kit below is supplied with adapter cable(s) for Polygraf ID and a Manometric Calibrator....
... Medtronic offers a family of single-use ... and convenience for you. This single-use catheter ... from the risk of infection and, because ... for patient care., ,We have water ...
... of single-use products to promote safety for ... single-use catheter reduces cross-contamination and helps protect ... and, because cleaning is eliminated, you have ... have water perfused manometric catheters for esophageal, ...
Medicine Products: